Q-Med Appoints Erika Kjellberg Eriksson as Chief Financial Officer

UPPSALA, Sweden, Nov. 15, 2002 (PRIMEZONE) -- Erika Kjellberg Eriksson, who was appointed acting Chief Financial Officer at Q-Med (Stockholm:QMED) on September 24, has been appointed permanent Chief Financial Officer.

Erika Kjellberg Eriksson comes from her positions as Group and Business Controller within Q-Med and has previously been Chief Financial Officer at Biophausia.

Q-Med AB (publ)

Bengt Agerup President and CEO

Queries should be addressed to:

Bengt Agerup, President and CEO
+ 46 (0)18-474 90 00 or +46 (0)70-974 90 25

Johan Hahnel, Director of Investor Relations and Corporate Communications
+46 (0)70-231 08 07

Q-Med AB (publ), Seminariegatan 21, SE-752 28 Uppsala, Sweden. Corporate identity number 556258-6882. Tel: +46(0)18-474 90 00. Fax: +46(0)18-474 90 01. E-mail:info@q-med.com. Home page: www.q-med.com

Information about Q-MED AB

Q-Med is a rapidly growing and profitable biotechnology/medical device company that develops, produces and markets medical implants. All products are based on the company's patented technology for the production of NASHA -- Non-Animal Stabilized Hyaluronic Acid. Q-Med's operations focus on the four areas of Esthetics, Orthopedics, Uro-Gynecology, and Cell Therapy and Encapsulation. The products RESTYLANE, RESTYLANE Fine Lines and PERLANE are used for the filling out of lips and facial wrinkles and today account for the majority of sales. Development of MACROLANE for body contouring, for example breast augmentation, is ongoing. DUROLANE, Q-Med's product for the treatment of osteoarthritis of the knee joint, has been approved in Europe since May 2001. DEFLUX is a product which has been approved in Europe and the USA for the treatment of vesicoureteral reflux (malformation of the urinary bladder) in children. ZUIDEX for the treatment of stress urinary incontinence in women has been sold in Europe since July 2002. Since July 2000 Q-Med has owned a majority interest in the American biotechnology company Ixion Biotechnology, Inc., with research within cell therapy for diabetes and within oxalate control. Q-Med today has 350 employees, with approximately 240 at the company's production facility and head office in Uppsala, 20 at Ixion and the remainder in wholly owned foreign sales companies. The Q-Med share was first listed on the O-list of the Stockholm Stock Exchange in December 1999.

This information was brought to you by Waymaker http://www.waymaker.net

The following files are available for download: